Fluconazole: Difference between revisions

From IDWiki
No edit summary
()
Line 18: Line 18:
|-
|-
!S
!S
!I
!SDD
!SDD
!I
!R
!R
!S
!S
!I
!SDD
!SDD
!I
!R
!R
|-
|-
Line 29: Line 29:
|0.5
|0.5
|≤2
|≤2
|—
|4
|4
|—
|≥8
|≥8
|≥17
|≥17
|—
|14-16
|14-16
|—
|≤13
|≤13
|-
|-
Line 50: Line 50:
|[[Candida glabrata]]
|[[Candida glabrata]]
|8
|8
|—
|—
|—
|≤32
|≤32
|—
|≥64
|≥64
|—
|—
|—
|≥15
|≥15
|—
|≤14
|≤14
|-
|-
Line 89: Line 89:
|1
|1
|≤2
|≤2
|4
|—
|—
|4
|≥8
|≥8
|≥17
|≥17
|—
|14-16
|14-16
|—
|≤13
|≤13
|-
|-
Line 100: Line 100:
|1
|1
|≤2
|≤2
|—
|4
|4
|—
|≥8
|≥8
|≥17
|≥17
|—
|14-16
|14-16
|—
|≤13
|≤13
|-
|-

Revision as of 15:10, 13 September 2020

Background

  • Antifungal in the triazole family with excellent bioavadilability but limited efficacy outside of Candida

Pharmacokinetics and Pharmacodynamics

  • Good oral bioavailability
  • Good CNS penetration
  • Fungistatic
  • Efficacy predicted by AUC/MIC ratio

Clinical Breakpoints

Species ECV (μg/mL) Breakpoints (μg/mL) Breakpoints (mm)
S SDD I R S SDD I R
Candida albicans 0.5 ≤2 4 ≥8 ≥17 14-16 ≤13
Candida dubliniensis 0.5
Candida glabrata 8 ≤32 ≥64 ≥15 ≤14
Candida guilliermondii 8
Candida krusei intrinsically resistant intrinsically resistant
Candida lusitaniae 1
Candida parapsilosis 1 ≤2 4 ≥8 ≥17 14-16 ≤13
Candida tropicalis 1 ≤2 4 ≥8 ≥17 14-16 ≤13
Cryptococcus neoformans 8
Cryptococcus gattii 16-32

Monitoring

  • ECG for QT prolongation
  • Liver enzymes for hepatitis

Adverse Drug Reactions